Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880700 | 0.91 | MTNR1A (0.47) | ALDH1A1HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL5880829 | 0.83 | FFAR1 (0.57) | POLB | |
| SCHEMBL9663109 | 0.82 | MAPK1 (0.51) | ALDH1A1HDAC1HDAC6HRH3MTNR1A | |
| SCHEMBL26637816 | 0.81 | ALDH1A1 (0.60) | ALDH1A1POLBKMT2A | |
| SCHEMBL2046622 | 0.80 | CTBP2 (0.55) | ALDH1A1MTNR1AMTNR1BPOLBSIGMAR1 | |
| SCHEMBL7332474 | 0.79 | TAAR1 (0.61) | HDAC1HDAC6MTNR1AMTNR1BTAAR1 | |
| SCHEMBL29092220 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HRH3MTNR1AMTNR1BTAAR1 | |
| SCHEMBL5880787 | 0.78 | EPHX2 (0.52) | ALDH1A1TAAR1KMT2A | |
| SCHEMBL28572234 | 0.78 | ALDH1A1 (0.59) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL268552 | 0.77 | RAB9A (0.69) | ALDH1A1HDAC1HDAC6MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | ALDH1A1 729/4885HDAC1 871/4885HDAC6 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.